View from City Road: Bitter pill for drugs firms
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.TWO SCHOOLS of thought are slugging it out for the hearts and minds of pharmaceutical investors. One says drugs companies are cheaper compared to the rest of the market than they have ever been and that is unjustified. Share prices are down, says the other camp, but the bad news has only just begun - a barrage of patent expiries will clobber the sector even further this year.
The latter group is winning the fight: since Black Wednesday, Glaxo has underperformed the rest of the market by 20 per cent, a similar showing to SmithKline Beecham. Wellcome has lagged the market by 10 per cent.
Bulls of the sector point to double-digit earnings and dividend growth. Although recovery stocks may look more attractive in the short term, profits from drugs are likely to look healthier than from the rest of industry in the long term. Worries about pricing pressures from the Clinton administration in the US will be proved unfounded.
The bears, led by Nomura, have come up with a new reason to shun the sector, however. Tenormin, ICI's heart drug, has lost 50 per cent of its sales in the year since its protection from generic rivals was lifted. The speed of its decline is unprecedented and suggests that, with continuing pressures on doctors to save money, patented drugs could come a cropper even more quickly.
Nomura reckons a quarter of the industry's profits could be affected by patent expiries or disputes this year. The list includes blockbusters like Glaxo's Zantac and even Wellcome's Retrovir, which faces a court challenge. The numbers may be a touch hyperbolic but the argument is compelling. The sector's underperformance is likely to continue.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments